Finance & Capital Markets

31. The Legend Steve Gorlin's Golden Rules 11/1/2023

    Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

32. Backpacks And Biotech With Luke Timmerman 11/15/2023

    From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. His unique perspective is hard to equal, and that perspective is, despite tough markets and tepid public sentiment, decidedly bullish. Luke's optimism is fed by sound logic gained from a career spent in observation mode, watching the development of purpose-built tools matched to address the fragility of human biology.

33. Financing Biopharma Innovation With Allan Shaw 12/19/2022

    Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. Allan offers up plenty of prognostication and professional insight in a preview of what's to come in 2023, complete with his signature "Allanisms" and colorful analogies. A can't-miss episode as we round the turn to a new year!

34. Biotech M&A Trends With Allan Shaw 3/21/2022

    On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market.

35. Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw 11/13/2025

    Allan Shaw, Chief Financial Officer and Chief Business Officer at CREATE Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

36. Mission-Driven Dementia Funding with DDF's Jonathan Behr 6/9/2024

    If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner.

37. Building Flagship Pioneering With Avak Kahvejian, Ph.D. 4/26/2023

    Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, Ph.D. Dr. Kahvejian counts Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines among the companies he's played a leading hand in launching. On this episode of the Business of Biotech, Kahvejian takes us under the hood of one of the most burgeoning businesses in biotech, sharing details on the people, processes, and technologies fueling its rapid growth.

38. Biotech C-Suite Construction With Allan Shaw 10/13/2024

    Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. If you're growing a biotech in these volatile times, this episode of the Business of Biotech offers veteran insight you won't want to miss.

39. CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D. 10/26/2020

    Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of non-viral T cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.

40. Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. 11/20/2025

    On this week's Business Of Biotech episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration.